When considering all patients, there is a significant difference (p < 0.01) in axillary response after NST between subtypes with the highest percentage of patients without axillary residual disease in HER2-positive breast cancer (87.5%), followed by the TN (60.0%) and ER-positive/HER2-negative subtypes (33.3%). This evidence concerns the gene ERBB2 and breast carcinoma.